NPS Turns Attention To Teduglutide After Preos “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
NPS says it will not continue development of Preos without a partner if FDA requests additional clinical trials.
You may also be interested in...
NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide
Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.
NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide
Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.
Preos “Approvable” Pending Additional Clinical Data, NPS Says
FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.